MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Operating Income 2011-2026 | ANIX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.7 M | -13.8 M | -11 M | -13.9 M | -13.1 M | -9.98 M | -11.9 M | -14.3 M | -6.08 M | -4.51 M | -945 K | -5.04 M | -7.92 M | -4.13 M | -5.03 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -945 K | -14.3 M | -8.89 M |
Quarterly Operating Income Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.72 M | - | -2.44 M | -3 M | -3.39 M | - | -3.59 M | -3.47 M | -3.61 M | - | -2.84 M | -2.56 M | -2.56 M | -10.3 M | -2.8 M | -3.59 M | -2.23 M | -9.06 M | -4.39 M | -2.44 M | -2.63 M | -7.74 M | -2.44 M | -2.67 M | -4.98 M | -9.76 M | -2.18 M | -2.59 M | -1.87 M | -8.88 M | -5.61 M | -1.4 M | -1.39 M | -4.34 M | -1.73 M | -1.21 M | -1.47 M | -3.6 M | -975 K | -1.15 M | 3.86 M | 233 K | -1.49 M | -2.13 M | -1.96 M | -3.48 M | -160 K | -1.36 M | -2.07 M | -6.14 M | -2.22 M | -1.85 M | -887 K | -2.41 M | -643 K | -878 K | -1.53 M | -4.02 M | -1.21 M | -1.29 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.86 M | -10.3 M | -2.9 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 114.7 | 0.85 % | $ 34.9 B |  USA |
 |
Celcuity
CELC
|
-172 M | $ 142.1 | 1.26 % | $ 6.64 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 3.81 | 59.41 % | $ 5.07 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 20.36 | 1.65 % | $ 590 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 17.25 | 5.12 % | $ 522 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 117.53 | 2.22 % | $ 14.7 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.58 | 2.03 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 116.36 | 1.1 % | $ 9.6 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 146.35 | 3.12 % | $ 23.3 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Lantheus Holdings
LNTH
|
311 M | $ 94.54 | -1.61 % | $ 6.38 B | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 160.56 | 2.86 % | $ 7.96 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 428.63 | 1.6 % | $ 12.4 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.01 | 1.18 % | $ 1.15 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 19.15 | -0.58 % | $ 429 M | USA |
 |
Natera
NTRA
|
-541 M | $ 202.54 | -1.16 % | $ 19.9 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 3.8 | -0.26 % | $ 352 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 8.33 | 4.78 % | $ 743 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 27.2 | 1.76 % | $ 25.8 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.04 | 5.78 % | $ 252 M | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
9.41 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.41 | 2.55 % | $ 5.54 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 255.67 | -0.68 % | $ 21.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 451.27 | -0.08 % | $ 170 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.64 | 5.06 % | $ 230 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 57.74 | 7.6 % | $ 3.45 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 8.84 | 0.11 % | $ 1.92 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 193.55 | -0.09 % | $ 21.5 B | USA |
 |
Waters Corporation
WAT
|
271 M | $ 341.66 | 0.12 % | $ 20.3 B | USA |